Horizon Pharma PLC (NASDAQ: HZNP) is one of 112 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Horizon Pharma PLC to similar businesses based on the strength of its risk, institutional ownership, profitability, dividends, earnings, analyst recommendations and valuation.
This is a summary of current ratings and recommmendations for Horizon Pharma PLC and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Horizon Pharma PLC||0||2||9||0||2.82|
|Horizon Pharma PLC Competitors||940||3771||5984||164||2.49|
Horizon Pharma PLC currently has a consensus price target of $18.91, suggesting a potential upside of 56.14%. As a group, “Pharmaceuticals” companies have a potential upside of 25.97%. Given Horizon Pharma PLC’s stronger consensus rating and higher probable upside, analysts clearly believe Horizon Pharma PLC is more favorable than its peers.
Insider and Institutional Ownership
82.3% of Horizon Pharma PLC shares are owned by institutional investors. Comparatively, 43.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.2% of Horizon Pharma PLC shares are owned by insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Horizon Pharma PLC and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Horizon Pharma PLC||-42.40%||22.85%||6.86%|
|Horizon Pharma PLC Competitors||-3,613.10%||-47.65%||-8.15%|
Earnings & Valuation
This table compares Horizon Pharma PLC and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Horizon Pharma PLC||$1.03 billion||-$46.52 million||-4.49|
|Horizon Pharma PLC Competitors||$7.86 billion||$2.50 billion||0.98|
Horizon Pharma PLC’s peers have higher revenue and earnings than Horizon Pharma PLC. Horizon Pharma PLC is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Horizon Pharma PLC has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, Horizon Pharma PLC’s peers have a beta of 0.86, indicating that their average stock price is 14% less volatile than the S&P 500.
Horizon Pharma PLC beats its peers on 9 of the 13 factors compared.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company’s marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.